YiChang HEC ChangJiang Pharmaceutical Co., Ltd. provided earnings guidance for the six months ended June 30, 2018. The company expected that the group will record an increase in profit attributable to equity shareholders of no less than 110% for the six months ended 30 June 2018, as compared to the six months ended 30 June 2017. The expected increase in profit attributable to equity shareholders is primarily attributed to: (i) the significant increase in the sales volume of the Company's key product Kewei and (ii) the continuous optimisation of the Company's academic promotion activities.